Shares of Exact Sciences have moved -1.5% today, and are now trading at a price of $55.33. In contrast, the S&P 500 index saw a -0.0% change. Today's trading volume is 1,679,101 compared to the stock's average volume of 2,818,549.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. Based in Madison, United States the company has 6,900 full time employees and a market cap of $10,437,341,184.
The company is now trading -19.64% away from its average analyst target price of $68.86 per share. The 25 analysts following the stock have set target prices ranging from $54.0 to $90.0, and on average give Exact Sciences a rating of buy.
Over the last 52 weeks, EXAS stock has risen 33.3%, which amounts to a 21.9% difference compared to the S&P 500. The stock's 52 week high is $72.83 whereas its 52 week low is $39.97 per share. With its net margins declining an average -7.6% over the last 6 years, Exact Sciences may not have a strong enough profitability trend to support its stock price.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 2,758,867 | -1,028,857 | -37 | -362.5 |
| 2023 | 2,499,766 | -204,149 | -8 | 73.33 |
| 2022 | 2,084,279 | -623,506 | -30 | 11.76 |
| 2021 | 1,767,087 | -595,625 | -34 | 38.18 |
| 2020 | 1,491,391 | -823,605 | -55 | -129.17 |
| 2019 | 876,293 | -213,090 | -24 |
